Survodutide delivers 16.6% weight loss in major phase 3 obesity trial

30th April 2026 Uncategorised 0

Boehringer Ingelheim reports significant reductions in weight

More: Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
Source: News